Surrozen, Inc. Form 8-K Summary
Business Context and Reporting Period
Surrozen, Inc. filed this Current Report on May 22, 2023, reporting matters from its 2023 Annual Meeting of Stockholders held on May 18, 2023. The voting record date was March 20, 2023. The company is listed on the Nasdaq Capital Market under the symbols SRZN and SRZNW and qualifies as an emerging growth company.
Key Financial Metrics and Liquidity
This filing does not provide revenue, profit or loss, cash flow, margin, debt, liquidity, capital resources or other operating financial metrics. It is limited primarily to shareholder voting results and the related auditor ratification.
Material Changes Versus the Prior Comparable Period
The filing does not report comparative financial information or material changes versus a prior period.
Meeting Results, Outlook and Risks
- Of 30,079,441 shares entitled to vote, 18,247,744 shares were represented in person or by proxy.
- Shao-Lee Lin, M.D., Ph.D., Mace Rothenberg, M.D., and David J. Woodhouse, Ph.D. were each elected as directors to serve until the 2026 annual meeting and until a successor is elected and qualified.
- Votes for, withheld and broker non-votes were 10,955,283, 4,205,346 and 3,087,115, respectively, for Dr. Lin; 11,843,735, 3,316,894 and 3,087,115 for Dr. Rothenberg; and 17,744,296, 3,316,894 and 3,087,115 for Dr. Woodhouse.
- Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, with 18,240,296 votes for, 499,008 against and 4,440 abstentions.
- No other matters were submitted for a vote. The filing provides no new management guidance, business outlook, contingencies or unusual financial items.
Important Facts for Investors to Verify
- Confirm the directors’ appointments and their service terms through subsequent proxy statements or company disclosures.
- Review subsequent filings for the results of the 2023 audit by Ernst & Young LLP and any changes in auditor status.
- Consult the company’s periodic reports for financial performance, cash runway, financing needs, clinical development updates and related risks, none of which are addressed in this 8-K.